Last reviewed · How we verify
intravenous lidocaine (IVL)
intravenous lidocaine (IVL) is a Local anesthetic; Class IB antiarrhythmic Small molecule drug developed by Ciusss de L'Est de l'Île de Montréal. It is currently FDA-approved for Acute ventricular arrhythmias (ventricular tachycardia, ventricular fibrillation), Perioperative analgesia and anesthesia adjunct, Chronic pain management (off-label).
Intravenous lidocaine blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses.
Intravenous lidocaine blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses. Used for Acute ventricular arrhythmias (ventricular tachycardia, ventricular fibrillation), Perioperative analgesia and anesthesia adjunct, Chronic pain management (off-label).
At a glance
| Generic name | intravenous lidocaine (IVL) |
|---|---|
| Sponsor | Ciusss de L'Est de l'Île de Montréal |
| Drug class | Local anesthetic; Class IB antiarrhythmic |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular; Anesthesia; Pain management |
| Phase | FDA-approved |
Mechanism of action
Lidocaine is a local anesthetic and antiarrhythmic agent that works by inhibiting sodium influx through voltage-gated sodium channels in excitable tissues. This suppresses the rapid depolarization phase of the action potential, raising the threshold for excitability. When administered intravenously, it is used primarily for acute ventricular arrhythmia suppression and as an adjunctive analgesic in perioperative and chronic pain settings.
Approved indications
- Acute ventricular arrhythmias (ventricular tachycardia, ventricular fibrillation)
- Perioperative analgesia and anesthesia adjunct
- Chronic pain management (off-label)
Common side effects
- Dizziness or lightheadedness
- Tremor or muscle twitching
- Nausea
- Hypotension
- Cardiac arrhythmias (at high doses)
- Seizures (at toxic doses)
Key clinical trials
- Lidocaine VS Hemodynamic, Metabolic and Hormonal Response (PHASE4)
- Impact of Intravenous Lidocaine During Colorectal Surgery on Pain and Immune Functions (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- intravenous lidocaine (IVL) CI brief — competitive landscape report
- intravenous lidocaine (IVL) updates RSS · CI watch RSS
- Ciusss de L'Est de l'Île de Montréal portfolio CI
Frequently asked questions about intravenous lidocaine (IVL)
What is intravenous lidocaine (IVL)?
How does intravenous lidocaine (IVL) work?
What is intravenous lidocaine (IVL) used for?
Who makes intravenous lidocaine (IVL)?
What drug class is intravenous lidocaine (IVL) in?
What development phase is intravenous lidocaine (IVL) in?
What are the side effects of intravenous lidocaine (IVL)?
What does intravenous lidocaine (IVL) target?
Related
- Drug class: All Local anesthetic; Class IB antiarrhythmic drugs
- Target: All drugs targeting Voltage-gated sodium channels
- Manufacturer: Ciusss de L'Est de l'Île de Montréal — full pipeline
- Therapeutic area: All drugs in Cardiovascular; Anesthesia; Pain management
- Indication: Drugs for Acute ventricular arrhythmias (ventricular tachycardia, ventricular fibrillation)
- Indication: Drugs for Perioperative analgesia and anesthesia adjunct
- Indication: Drugs for Chronic pain management (off-label)
- Compare: intravenous lidocaine (IVL) vs similar drugs
- Pricing: intravenous lidocaine (IVL) cost, discount & access